Scinai Immunotherapeutics Ltd. (SCNI) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 487.67K | 386.5K | 386.5K | 206K | 168K | 284K | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | 26.18% | 36.09% | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 1.6M | 1.02M | 1.02M | 373K | 417K | 448K | 157.73K | 84.91K | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 328.63% | 264.3% | 264.3% | 181.07% | 248.21% | 157.75% | - | - | - | - | - | - |
| Gross Profit | -1.11M | -635K | -635K | -167K | -249K | -164K | -157.73K | -84.91K | 0 | 0 | 0 | 0 |
| Gross Margin % | -228.63% | -164.29% | -164.29% | -81.07% | -148.21% | -57.75% | - | - | - | - | - | - |
| Gross Profit Growth % | -75.59% | -287.2% | -302.59% | -96.68% | - | - | - | - | - | - | - | - |
| Operating Expenses | 1.35M | 1.25M | 1.25M | 2.1M | 2.17M | -4.12M | 2.05M | 1.82M | 2.1M | -8.97M | 3.19M | -4.32M |
| OpEx % of Revenue | 275.87% | 322.51% | 322.51% | 1017.48% | 1292.26% | -1450.35% | - | - | - | - | - | - |
| Selling, General & Admin | 719.04K | 628K | 497.4K | 759K | 764K | 519K | 484K | 1.13M | 968K | 1.14M | 1.19M | 1.81M |
| SG&A % of Revenue | 147.44% | 162.48% | 128.69% | 368.45% | 454.76% | 182.75% | - | - | - | - | - | - |
| Research & Development | 626.3K | 618.5K | 1.29M | 1.34M | 1.41M | 1.22M | 1.57M | 627K | 1.13M | 1.45M | 2M | 1.74M |
| R&D % of Revenue | 128.43% | 160.03% | 333.51% | 649.03% | 837.5% | 428.17% | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | -539.9K | 0 | 0 | -1000K | 0 | 63K | 0 | -1000K | 0 | -1000K |
| Operating Income | -2.46M | -1.88M | -1.88M | -2.26M | -2.42M | 3.96M | -2.05M | -1.82M | -2.1M | 8.97M | -3.19M | 4.32M |
| Operating Margin % | -504.5% | -486.8% | -486.8% | -1098.54% | -1440.48% | 1392.61% | - | - | - | - | - | - |
| Operating Income Growth % | -30.76% | -147.57% | 8.31% | -24.14% | -15.13% | -55.89% | 35.59% | -142.17% | -293.91% | 374.81% | -21.84% | -43.7% |
| EBITDA | -2.01M | -1.53M | -1.53M | -1.76M | -1.92M | 4.45M | -1.9M | -1.74M | -1.96M | 9.11M | -3.05M | 4.46M |
| EBITDA Margin % | -411.86% | -395.73% | -395.73% | -856.31% | -1144.05% | 1567.25% | - | - | - | - | - | - |
| EBITDA Growth % | -31.32% | -134.36% | 19.33% | -1.44% | 1.79% | -51.15% | 37.8% | -138.96% | -250.29% | 392.25% | -22.85% | -43.27% |
| D&A (Non-Cash Add-back) | 451.77K | 352K | 352K | 499K | 498K | 496K | 156K | 84K | 145K | 145.33K | 138K | 140.5K |
| EBIT | -2.46M | -1.88M | -1.19M | -2.17M | 12.34M | -2.03M | -1.93M | -1.82M | -2.1M | -2.6M | -3.19M | -6.74M |
| Net Interest Income | -111.7K | -185.5K | 10.94K | -37K | 12.88M | -295K | -231K | -512.5K | 5.21M | -1.15M | -325.92K | 4M |
| Interest Income | 0 | 0 | 10.94K | 0 | 14.76M | 0 | 2.56K | 0 | 5.19M | 0 | 0 | 4M |
| Interest Expense | 111.7K | 185.5K | 10.94K | 37K | 1.88M | 293.92K | 233.56K | 512.5K | 0 | 1.15M | 325.92K | 0 |
| Other Income/Expense | 6.03M | -185.5K | -185.5K | 33K | 12.88M | -6.28M | -107K | -507K | 5.21M | -12.73M | -329K | -4.85M |
| Pretax Income | 3.57M | -2.07M | -2.07M | -2.23M | 10.46M | -2.32M | -2.16M | -2.33M | 3.11M | -3.76M | -3.52M | -529K |
| Pretax Margin % | 731.49% | -534.8% | -534.8% | -1082.52% | 6223.21% | -817.61% | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | 3.57M | -2.07M | -2.07M | -2.23M | 10.46M | -2.32M | -2.16M | -2.33M | 3.11M | -3.76M | -3.52M | -529K |
| Net Margin % | 731.49% | -534.8% | -534.8% | -1082.52% | 6223.21% | -817.61% | - | - | - | - | - | - |
| Net Income Growth % | 272.58% | 10.98% | 4.26% | 4.29% | 236.5% | 38.28% | 38.58% | -340.45% | 195.62% | -26.11% | -42.02% | -144.45% |
| Net Income (Continuing) | 3.57M | -2.07M | -2.07M | -2.23M | 10.46M | -2.32M | -2.16M | -2.33M | 3.11M | -3.76M | -3.52M | -529K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 3840.00 | -1.20 | -1.20 | -8.80 | 12.40 | -3.60 | -4.40 | -10.40 | 26480.00 | -44520.00 | -48000.00 | -46800.00 |
| EPS Growth % | 320100% | 66.67% | 72.73% | 15.38% | -99.95% | 99.99% | 99.99% | 99.98% | 17.58% | 30.35% | 9.71% | 26.23% |
| EPS (Basic) | 3840.00 | -1.20 | -1.20 | -8.80 | 12.40 | -3.60 | -4.40 | -7.60 | 26480.00 | -44520.00 | -43400.00 | -10880.00 |
| Diluted Shares Outstanding | 946 | 1.59M | 806.37K | 806.37K | 843.57K | 637.6K | 506.54K | 300.38K | 469.22K | 337.96K | 323.81K | 194.35K |
| Basic Shares Outstanding | 946 | 1.59M | 806.37K | 806.37K | 843.57K | 637.6K | 506.54K | 223.32K | 469.22K | 337.96K | 292.92K | 194.35K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |